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ABSTRACT 
 
Objectives: To evaluate the bone health and vitamin D levels of a cohort of patients with relapses of 
multiple sclerosis (MS) and to propose an algorithm for the management of bone health in this patient 
group. 
Methods: We prospectively studied 56 consecutive patients from our acute relapse clinic. 3 patients 
were excluded from analysis as they were not deemed to have experienced an acute MS relapse. Bone 
health was assessed with vitamin D levels and Dual Energy X-ray Absorptiometry (DEXA) scanning 
(10 patients failed to attend for DEXA). Statistical analyses were used to compare groups and identify 
predictive variables. A review of the literature led to a proposed management protocol. 
Results: Pre-relapse the baseline EDSS was ≤6.5 in all subjects, and <4.0 in the majority (66%). Most 
received corticosteroids. 51% had low bone mineral density (BMD) as defined by a T-score less than -
1.0 on DEXA scanning. Three were osteoporotic (T-score less than -2.5). Thirty one of fifty (62%) 
subjects were Vitamin D deficient (25(OH)D less than 50nmol/L). A range of variables, including 
previous corticosteroid usage, were not significantly predictive of reduced BMD. 
Conclusions:  There was a high frequency of both low BMD and Vitamin D deficiency in this cohort 
of relatively young and largely ambulatory patients experiencing MS relapses. Current tools, such as 
the WHO FRAX algorithm, are inadequate in assessing bone status and fracture risk in this patient 
group, predominantly as they are focused on older age groups. We propose a simple clinical 
management algorithm. 
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INTRODUCTION 
Metabolic bone disease is under-recognised and under-treated in multiple sclerosis (MS). There is a 
lack of evidence and guidance for the recognition and treatment of metabolic bone disease, 
particularly in patients with relapsing-remitting MS (RRMS) who may frequently be exposed to high 
doses of corticosteroids. Patients with MS (PwMS) have higher rates of fractures than the general 
population[1-2] and reduced bone mineral density (BMD) compared to healthy controls[3]. Increasing 
neurologic impairment as categorised by the Kurtzke Expanded Disability Status Scale (EDSS)[4] is a 
key factor contributing to osteopenia and osteoporosis in PwMS.[5-7] However, while poor bone 
health is common in many chronic neurological diseases, reduced BMD has been identified even in 
the early stages of MS when patients are fully ambulatory and EDSS is low.[8] High-dose 
methylprednisolone (intravenous or oral, 3-5g) up to 2-3 times/year is a common treatment for 
relapses of MS, and is effective in reducing relapse duration.[9] Whilst long-term steroid treatment is 
a clear risk factor for osteopenia (and osteoporosis) as recognised in the FRAX algorithm; the position 
is much less clear for pulses of steroid which last for under a week. Short-term corticosteroid therapy 
has been shown to affect the biochemical markers of bone turnover in PwMS[10], but the evidence for 
corticosteroid-induced osteopenia in this group is conflicting.[5,11-12] 
 
Management of bone health in this population is challenging, as it is difficult to stratify fracture risk. 
The WHO FRAX calculator (www.shef.ac.uk/FRAX/) is a tool for predicting risk of fracture, 
however it has a number of limitations in the setting of MS. It is validated for a general population 
cohort over the age of 40[13], while in a typical relapse clinic the average age is 40 and women are 
pre-menopausal[14]. Steroids are only included as a risk factor in the FRAX calculation if the dose is 
at least 5mg/day for more than 3 months, MS is not included as an independent risk factor, and it does 
not take into account Vitamin D deficiency which is associated with MS[15] and an important 
modifier of bone health. An alternative, the recent Qfracture tool, includes a wider age range and 
additional risk factors than the FRAX,[16] however even with this tool the projection of the risk of 
fracture in this specific population is limited and likely to be an underestimation.[17] Bazelier et al. 
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recently described a clinical risk score for the estimation of fracture risk for PwMS which is likely to 
give a better estimation of fracture risk in this specific population.[18] However this scoring system 
needs further validation before routine use in a clinical context. 
 
To examine these issues, we wanted to determine the bone status of a sequential cohort of patients 
attending an acute MS relapse clinic, who received high-dose steroid treatment. We aimed to identify 
any predictive variables for reduced BMD and create a simple management algorithm to improve 
quality of clinical care for this patient group. 
 
METHODS 
 
The National Hospital of Neurology and Neurosurgery MS relapse service has been described 
before,[19] but in brief, PwMS are tele-triaged by an MS-trained healthcare professional and then, if a 
significant relapse is occurring, proceed to a weekly ambulatory outpatient clinic. After assessment, if 
clinically indicated, a standard steroid regime of intravenous methylprednisolone 1g/day for 3 days is 
used along with multi-disciplinary therapy input.  
 
We included 56 consecutive patients from our clinic in this quality improvement study. Following 
medical assessment, 3 patients were deemed to have symptoms which were not compatible with an 
acute relapse and were excluded from statistical analysis. Demographic information was recorded for 
all patients, as well as details of MS type and duration, current medications including calcium/vitamin 
D supplementation, treatment with corticosteroids in the preceding two years (intravenous or oral 
form) and both pre-relapse  and in-relapse EDSS. Lifestyle variables relevant to bone health were also 
recorded, including body mass index (BMI), smoking status, alcohol consumption, menopausal status 
and history of fragility fractures. 
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Blood tests (total 25-hydroxyvitamin D [25(OH)D] thyroid function tests, parathyroid hormone, renal, 
liver and bone profiles) were taken at the time of clinic attendance (between January and April). 25-
hydroxyvitamin D2 and 25-hydroxyvitamin D3 were measured using liquid chromatography tandem 
mass spectrometry (LC-MS/MS), and these were combined to give total 25(OH)D. 25(OH)D levels 
below 7 nmol/L were arbitrarily scored as 5 nmol/L. Dual energy X-ray absorptiometry (DEXA) 
scanning was arranged within three months of attendance at clinic; DEXA T-scores and Z-scores were 
obtained for the hip, neck of femur and lumbar spine. T-scores compare BMD of an individual with 
that of a young healthy population, with osteoporosis defined as SD ≤-2.5 from the mean, and 
osteopenia as SD ≤-1.0 from the mean. A Z-score compares an individual’s BMD to that of an age 
and sex matched population. 10 subjects failed to attend for scheduled DEXA scans, and comparing 
this group to the 43 subjects who did attend for DEXA, there were no significant differences in terms 
of gender, age, MS duration or EDSS. 
 
FRAX scores were calculated using the online WHO FRAX Calculator.[20] For patients under 40 the 
model calculates the probability of a fracture at age 40 (likely to result in an overestimation of fracture 
risk in younger subjects). 
 
Comparisons between the groups were made with Student’s t test for continuous variables and 
Fisher’s exact test for categorical variables. Logistic regression was used to identify any predictive 
variables for osteopenia/osteoporosis, and linear regression to identify the lowest measured T score in 
an individual. BMI, age, sex, vitamin D levels, EDSS pre- and in-relapse, FRAX scores without bone 
density, smoking status and previous steroid exposure were entered as variables. Patients consented to 
inclusion and ethical approval was not required for this study as it was a service evaluation.[21] 
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RESULTS 
The cohort characteristics are described in Table 1. The mean age of all subjects was 39.6 years and 
the majority of patients (66%, 95% C.I. 52 to 80%) were fully ambulatory pre-relapse with an EDSS 
of <4.0. The maximum pre-relapse EDSS of any subject was 6.5, and the majority (87%, 95% C.I. 78 
to 96%) were classified as having relapsing remitting MS (RRMS). In-relapse EDSS was ≥ 4.0 in the 
majority of subjects (80%, 95% C.I. 68 to 92%), with 21 subjects moving from being fully 
ambulatory (EDSS <4.0) to having some mobility limitation (EDSS ≥ 4.0) as a result of relapse. A 
sensitivity analysis was performed assigning EDSS levels <4 as either 0 or 4 and there was no 
significant difference in the outcome of statistical analysis. Mean 25(OH)D was 45.6 nmol/L (range 
5.0 to 162 nmol/L). 96% of patients were treated with steroids as a result of their attendance in the MS 
relapse clinic.  
 
Table 2 shows the 43 subjects with DEXA results (10 did not attend their appointment). DEXA scans 
were performed at mean 58 days after corticosteroid treatment. 22 (51%) patients were osteopenic (3 
of whom were osteoporotic). Two of the 3 osteoporotic patients were post-menopausal women. 
Thirty-one of 50 (62%, 95% C.I. 49 to 75%) patients were vitamin D deficient based on the 50nmol/L 
cut-off recommended by the United States Endocrine Society.[22] Prevalence of Vitamin D 
deficiency in our cohort was higher than prevalence in the British population (range 3.2% to 46.6% 
depending on seasonal variation and cut-offs of either 25nmol/L or 40nmol/L).[23] 25(OH)D levels 
were measured between January and April and are likely to reflect some seasonal variation (25(OH)D 
serum levels reach an annual trough in February).[24] While methods of adjusting Vitamin D for 
month and season have been described,[25] this standardisation method is not routinely used in 
clinical practice and cut-offs for sufficiency/deficiency apply year-round. However, there is a lack of 
global consensus on exact serum cut-offs for vitamin D deficiency/insufficiency.[26] 
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Table 3 compares patients with normal BMD to those with osteopenia/osteoporosis. None of the 
variables of 25(OH)D levels, previous corticosteroid usage and pre-relapse EDSS were significantly 
different between these groups. There was no significant difference in FRAX scores pre-DEXA 
scanning comparing patients with normal BMD versus osteopenia/osteoporosis. The only significant 
difference between the groups resulted from the comparison of FRAX scores post-DEXA scanning. 
 
Using logistic regression, no variable significantly predicted the binary outcome of 
osteoporosis/osteopenia versus normal bone density. Similarly, standard linear regression found no 
significant predictors of lowest DEXA T-score in this study. 
DISCUSSION 
Significantly reduced BMD (approximately half of all patients [51%, 95% C.I. 36.1 to 65.9]) and 
25(OH)D deficiency (approximately two thirds of all patients [62%, 95% C.I. 48.6 to 75.4]) were  
common in this sequential cohort of about 50 patients assessed following an MS relapse, despite the 
young average age (majority pre-menopausal) and low levels of pre-relapse disability (66% EDSS 
<4.0, 95% C.I. 52 to 80%). However statistical analysis failed to reveal any significant differences 
between those with normal BMD and those with osteopenia in terms of: 25(OH)D levels, relapse 
frequency or disability level  (either pre-relapse or in-relapse EDSS).  
 
It has been difficult to elucidate the reason for reduced bone density in the early stages of MS. 
Various studies have shown heterogeneity of predictive variables. Kirbas et al.[27] and Moen et 
al.[28] suggest that this points to a shared aetiology of MS and osteopenia/osteoporosis. Sioka et al. 
have suggested that the inflammatory process with relapsing MS may be detrimental to bone status[3], 
which is supported in the literature relating to rheumatic disease.[29] This hypothesis is supported by 
the disproportionately low BMD we have demonstrated in our study of young ambulatory patients 
with active MS. Finally, the evidence for an epidemiological association between MS and Vitamin D 
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deficiency continues to accrue[30], and vitamin D levels are an important long-term modifier of bone 
health.[31]   
 
Our study shows that the frequency of steroid course over the preceding 2 years did not influence 
BMD, and supports other studies demonstrating no detrimental impact of short-term high-dose 
steroids.[12] Indeed, glucocorticoid-induced osteoporosis is only considered a risk in those patients 
who receive at least 5mg Prednisolone (or equivalent dose of other glucorticoids) for at least 3 
months.[32] However there is increasing evidence that the impact of steroids on bone health extends 
beyond BMD. Patients on long term steroids experience fractures at a higher BMD than controls[33] 
and steroids have been shown to have a negative impact on bone modeling and architecture that is not 
detected in standard DEXA scanning.[34,35] Further longitudinal studies are required to examine the 
influence of high-dose corticosteroid use on long-term outcome measures (including fracture rates) in 
the MS population.  
 
The question arises as to how to assess the bone health of patients attending with an MS relapse, if it 
had not been previously or recently examined. From this data, one approach would be to measure the 
Vitamin D and BMD using DEXA of all patients attending with a relapse, since their risk appears to 
be so high. However, considering the young age of this population and the resource utilisation this 
would require, we advocate a more conservative approach to identify patients in need further 
investigation. 
 
Considering the above, we suggest here an algorithm to manage the inter-related issues of 25(OH)D 
deficiency and reduced BMD (Figure 1). Initial assessment includes evaluation of lifestyle factors 
along with blood tests relevant to bone health, including serum 25(OH)D on a yearly basis. All 
patients should be advised regarding conservative measures to maintain bone density. 
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Vitamin D Deficiency  
Patients should be offered Vitamin D supplementation if their serum level is deficient (<50nmol/L). In 
particular as table 1 shows, less than 20% of this cohort was taking vitamin D/calcium supplements, 
before the high prevalence of reduced BMD was identified from this study. While 50nmol/L is 
considered a lower cut-off for Vitamin D deficiency, 70-80 nmol/L should be targetted as the optimal 
serum level for bone health[37,38]. To achieve target levels, doses up to 10000 IU per day appear to 
be safe.[39] We recommend supplementation with Cholecalciferol (Vitamin D3) at a dose of 10000 or 
20000 units weekly which should be sufficient to achieve target serum Vitamin D levels. Calcium 
should be supplemented with 1g Calcium Carbonate daily if there is dietary deficiency.[40] Serum 
calcium should be measured after 1 month, as Vitamin D supplementation can unmask 
hyperparathyroidism.[41] We recommend reassessing Vitamin D levels after 6 months of 
supplementation, when a steady state is achieved.[41] Dosing can be adjusted if necessary at this 
point, including dose reduction if required (in view of recent evidence that 25(OH)D levels greater 
than 120 nmol/L are associated with increased all-cause mortality [42]). Once a steady state of 
sufficiency is achieved, draft guidelines from the National Osteoporosis Society indicate that routine 
monitoring of 25(OH)D is unnecessary[41], however it would seem prudent to monitor calcium levels 
annually, in case of hypercalcaemia. 
 
DEXA Scanning 
Next we consider which patients require formal DEXA scanning. As highlighted by Dobson et 
al.,[40] there is a lack of disease specific evidence or guidelines for the monitoring of bone health in 
this cohort, but a practical and proactive approach should be employed for early identification of those 
at increased risk of fractures. DEXA scanning is a non-invasive imaging method with a very low 
radiation dose (approximately 2.5 microSv).[43] Post-menopausal women are at highest risk of 
osteoporosis, and we recommend that a DEXA scan is included in initial assessment. For the rest of 
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the patient population (men and pre-menopausal women), we would recommend proceeding to DEXA 
scan if mobility is impaired (i.e. pre-relapse EDSS ≥ 4.0) or falls risk is high. For patients without 
these additional risks, we consider the FRAX or QFracture tools to be a useful adjunctive assessment. 
We have demonstrated that FRAX scores calculated pre-DEXA imaging have limited predictive value 
in our study population, and this supports the need for a management approach specific to MS. 
However the FRAX and Qfracture tools have been validated in large populations and may certainly 
have a role in identifying those patients with significant risk factors for reduced BMD independent of 
MS e.g. comorbid diabetes or rheumatoid arthritis. Management of patients with reduced BMD 
identified on DEXA scan should be in accordance with local guidelines e.g. the National Osteoporosis 
Guideline Group in Britain.[44]  
 
Timing of DEXA scanning 
In our study we carried out DEXA scans at a mean of 58 days after the relapse clinic assessment. This 
is more practical than completing DEXA imaging in the early acute stage of a relapse, as allowing 
some time for recovery will likely give a better reflection of long-term BMD. When interpreting 
DEXA results in this cohort it is also reasonable to assume that regional osteoporosis can occur in the 
context of a relapse, similar to that described in paretic limbs of stroke patients.[45] Areas of regional 
paresis should be avoided if possible during DEXA imaging. If regional osteoporosis is demonstrated 
in a paretic region affected by acute relapse, it may be prudent to delay a treatment decision and 
repeat DEXA scanning after 6 months to allow a full cycle of bone remodelling. 
 
Strengths and limitations 
The strengths of our study include the multi-modal assessment of bone status of patients (lifestyle 
factors, FRAX assessment, Vitamin D status and BMD), minimal exclusion criteria and our proposal 
of a clinical algorithm for management of bone health in this population. Our approach is novel as we 
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chose to focus on a cohort of patients with active disease experiencing MS relapses. The lack of 
controls and the non-attendance of 10 subjects for DEXA scanning can be considered limitations. 
While our study reflects an average population in our relapse clinic, factors such as relapse frequency, 
regional and seasonal variation in Vitamin D limit the generalisability of our results across this 
population and across regions, so we have considered our results in the context of the relevant 
literature when designing our clinical algorithm.  
 
Conclusion 
Our study supports recent evidence that bone loss begins early in MS and illustrates that predicting 
BMD in this group is difficult. Bone loss is likely to increase with disease progression so it is 
necessary to identify those at risk of fractures early, treat appropriately and continue to monitor over 
the long-term. The algorithm proposed here should aid clinicians in early identification and 
management of patients at risk of fractures. While the algorithm has been designed considering our 
patient group (patients in an acute relapse clinic), we feel it could be applied in any similar clinical 
setting i.e. patients with RRMS on disease modifying medications, which could be the focus of further 
work.  
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